Cerus (CERS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced virtually with board and leadership introductions and confirmation of the agenda.
Inspector of Election and independent auditors were introduced, and meeting procedures were outlined.
Notice of meeting and quorum were confirmed, allowing business to proceed.
Board and executive committee updates
Vivek Jayaraman will succeed the current CEO as President and CEO effective July 1st.
Shareholder proposals
Four proposals were presented: election of two directors, amendment of the 2024 Equity Incentive Plan, advisory approval of executive compensation, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cerus
- Q2 2026 product revenue up 10% to $57.4M, guidance raised, and liquidity improved.CERS
Q2 2026 - Q1 2026 revenue up 23%, product revenue up 24%, and net loss narrowed to $1.6 million.CERSQ1 2026
- Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.CERSCorporate presentation
- Proxy covers director elections, equity plan expansion, pay, auditor, and governance highlights.CERSProxy filing
- Virtual vote set for June 2026 on directors, equity plan, pay, and auditor ratification.CERSProxy filing
- 2025 revenue rose 16% with narrowing losses and surging INTERCEPT Fibrinogen Complex demand.CERSQ4 2025
- Q2 revenue up 16%, net loss narrowed, and 2024 guidance raised on strong North American growth.CERSQ2 2024
- Q3 2024 product revenue up 16%, net loss narrowed, and full-year guidance raised.CERSQ3 2024
- BARDA awards up to $248M for U.S. program; Europe plans new submission after CE Mark setback.CERSStudy Update